These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 15622324)

  • 21. Activation and coreceptor expression of T lymphocytes induced by highly active antiretroviral therapy in Chinese HIV/AIDS patients.
    Zhang ZN; Shang H; Jiang YJ; Liu J; Dai D; Diao YY; Geng WQ; Jin X; Wang YN
    Chin Med J (Engl); 2006 Dec; 119(23):1966-71. PubMed ID: 17199940
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Serum neopterin, an immune activation marker, independently predicts disease progression in advanced HIV-1 infection.
    Mildvan D; Spritzler J; Grossberg SE; Fahey JL; Johnston DM; Schock BR; Kagan J
    Clin Infect Dis; 2005 Mar; 40(6):853-8. PubMed ID: 15736019
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Breast milk CD4+ T cells express high levels of C chemokine receptor 5 and CXC chemokine receptor 4 and are preserved in HIV-infected mothers receiving highly active antiretroviral therapy.
    Kourtis AP; Ibegbu CC; Theiler R; Xu YX; Bansil P; Jamieson DJ; Lindsay M; Butera S; Duerr A
    J Infect Dis; 2007 Apr; 195(7):965-72. PubMed ID: 17330786
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antiretroviral therapy based on protease inhibitors as a protective factor against liver fibrosis progression in patients with chronic hepatitis C.
    Macías J; Mira JA; López-Cortés LF; Santos I; Girón-González JA; González-Serrano M; Merino D; Hernández-Quero J; Rivero A; Merchante N; Trastoy M; Carrillo-Gómez R; Arizcorreta-Yarza A; Gómez-Mateos J; Pineda JA
    Antivir Ther; 2006; 11(7):839-46. PubMed ID: 17302246
    [TBL] [Abstract][Full Text] [Related]  

  • 25. HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy.
    Steingrover R; Pogány K; Fernandez Garcia E; Jurriaans S; Brinkman K; Schuitemaker H; Miedema F; Lange JM; Prins JM
    AIDS; 2008 Aug; 22(13):1583-8. PubMed ID: 18670217
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CD4 lymphocyte percentage predicts disease progression in HIV-infected patients initiating highly active antiretroviral therapy with CD4 lymphocyte counts >350 lymphocytes/mm3.
    Hulgan T; Raffanti S; Kheshti A; Blackwell RB; Rebeiro PF; Barkanic G; Ritz B; Sterling TR
    J Infect Dis; 2005 Sep; 192(6):950-7. PubMed ID: 16107946
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term study of intraocular pressure changes in patients with human immunodeficiency virus treated with highly active antiretroviral therapy.
    Kozak I; LaBree L; Azen SP; Cheng L; Reagan NL; Freeman WR
    Ophthalmology; 2006 Mar; 113(3):451-5. PubMed ID: 16513459
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Influence of exercise training and age on CD14+ cell-surface expression of toll-like receptor 2 and 4.
    Stewart LK; Flynn MG; Campbell WW; Craig BA; Robinson JP; McFarlin BK; Timmerman KL; Coen PM; Felker J; Talbert E
    Brain Behav Immun; 2005 Sep; 19(5):389-97. PubMed ID: 15963685
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Haemoglobin and albumin as markers of HIV disease progression in the highly active antiretroviral therapy era: relationships with gender.
    Shah S; Smith CJ; Lampe F; Youle M; Johnson MA; Phillips AN; Sabin CA
    HIV Med; 2007 Jan; 8(1):38-45. PubMed ID: 17305931
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sublethal infection of C57BL/6 mice with Salmonella enterica Serovar Typhimurium leads to an increase in levels of Toll-like receptor 1 (TLR1), TLR2, and TLR9 mRNA as well as a decrease in levels of TLR6 mRNA in infected organs.
    Tötemeyer S; Kaiser P; Maskell DJ; Bryant CE
    Infect Immun; 2005 Mar; 73(3):1873-8. PubMed ID: 15731092
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CD38 expression on CD8 T cells has a weak association with CD4 T-cell recovery and is a poor marker of viral replication in HIV-1-infected patients on antiretroviral therapy.
    Steel A; John L; Shamji MH; Henderson DC; Gotch FM; Gazzard BG; Kelleher P
    HIV Med; 2008 Feb; 9(2):118-25. PubMed ID: 18257774
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunological response to highly active antiretroviral therapy in children with clinically stable HIV-1 infection.
    Rosenblatt HM; Stanley KE; Song LY; Johnson GM; Wiznia AA; Nachman SA; Krogstad PA;
    J Infect Dis; 2005 Aug; 192(3):445-55. PubMed ID: 15995958
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Toll-like receptor 2-positive and Toll-like receptor 4-positive cells in adenoids of children exposed to passive smoking.
    Ricci A; Avanzini MA; Scaramuzza C; Castellazzi AM; Marconi M; Marseglia GL
    J Allergy Clin Immunol; 2005 Mar; 115(3):631-2. PubMed ID: 15753915
    [No Abstract]   [Full Text] [Related]  

  • 34. C-reactive protein is a marker for human immunodeficiency virus disease progression.
    Lau B; Sharrett AR; Kingsley LA; Post W; Palella FJ; Visscher B; Gange SJ
    Arch Intern Med; 2006 Jan; 166(1):64-70. PubMed ID: 16401812
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Increased NKG2A found in cytotoxic natural killer subset in HIV-1 patients with advanced clinical status.
    Zhang R; Xu J; Hong K; Yuan L; Peng H; Tang H; Ma P; Zhang Y; Xing H; Ruan Y; Shao Y
    AIDS; 2007 Dec; 21 Suppl 8():S9-17. PubMed ID: 18172398
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Expression of Toll-like receptors in healthy and allergic conjunctiva.
    Bonini S; Micera A; Iovieno A; Lambiase A; Bonini S
    Ophthalmology; 2005 Sep; 112(9):1528; discussion 1548-9. PubMed ID: 16023216
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Illicit drug use and HIV-1 disease progression: a longitudinal study in the era of highly active antiretroviral therapy.
    Lucas GM; Griswold M; Gebo KA; Keruly J; Chaisson RE; Moore RD
    Am J Epidemiol; 2006 Mar; 163(5):412-20. PubMed ID: 16394200
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Overview of HIV.
    Klimas N; Koneru AO; Fletcher MA
    Psychosom Med; 2008 Jun; 70(5):523-30. PubMed ID: 18541903
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hepatitis C virus coinfection and HIV load, CD4+ cell percentage, and clinical progression to AIDS or death among HIV-infected women: Women and Infants Transmission Study.
    Hershow RC; O'Driscoll PT; Handelsman E; Pitt J; Hillyer G; Serchuck L; Lu M; Chen KT; Yawetz S; Pacheco S; Davenny K; Adeniyi-Jones S; Thomas DL
    Clin Infect Dis; 2005 Mar; 40(6):859-67. PubMed ID: 15736020
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evolution of hepatitis B serological markers in HIV-infected patients receiving highly active antiretroviral therapy.
    Sheng WH; Kao JH; Chen PJ; Huang LM; Chang SY; Sun HY; Hung CC; Chen MY; Chang SC
    Clin Infect Dis; 2007 Nov; 45(9):1221-9. PubMed ID: 17918088
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.